Designed to address blood glucose levels in type 2 diabetes to alleviate hyperglycemic symptoms and support long-term metabolic control in adult patients.
Mechanism of Action
Sitagliptin inhibits the DPP-4 enzyme, which increases the levels of incretin hormones. These hormones stimulate the pancreas to release insulin and signal the liver to stop producing sugar, helping to normalize blood glucose levels.
Route of Administration
Oral
Onset Time
1–4 hours
Duration
24 hours
Contraindications
Type 1 diabetes, Diabetic ketoacidosis, Hypersensitivity to sitagliptin
Severe Adverse Events
Acute pancreatitis, Severe allergic reactions, Heart failure, Kidney impairment, Severe joint pain
Information for Sitagliptin is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
